{"name":"PT. JES Kasih Nusantara Sejahterah","slug":"pt-jes-kasih-nusantara-sejahterah","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dendritic cell immunotherapy","genericName":"Dendritic cell immunotherapy","slug":"dendritic-cell-immunotherapy","indication":"Cancer (specific indication not publicly detailed for this investigational product)","status":"phase_3"}]}],"pipeline":[{"name":"Dendritic cell immunotherapy","genericName":"Dendritic cell immunotherapy","slug":"dendritic-cell-immunotherapy","phase":"phase_3","mechanism":"Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells.","indications":["Cancer (specific indication not publicly detailed for this investigational product)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}